Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Setmelanotide

MARKETED

melanocortin-4 receptor (MC4R) agonist

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 1Low evidence 0Very low evidence 0

Setmelanotide is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Setmelanotide MARKETED
Weight change Decrease
Moderate evidence

In severe obesity from POMC or LEPR deficiency, ~1 year of setmelanotide produced significant weight loss and reduced hunger: >=10% weight loss in 80% (8/10) of...

Clement et al., Lancet Diabetes Endocrinol 2020 Source
Full findingIn severe obesity from POMC or LEPR deficiency, ~1 year of setmelanotide produced significant weight loss and reduced hunger: >=10% weight loss in 80% (8/10) of POMC-deficiency and 45% (5/11) of LEPR-deficiency participants. Marketed (Imcivree) for genetic MC4R-pathway obesity and Bardet-Biedl syndrome; positive in acquired hypothalamic obesity and ages 2-5 (VENTURE).
PopulationSingle-arm open-label multicentre phase 3, POMC and LEPR deficiency, participants aged >=6y; ~1-year endpoint
Fundingindustry - Rhythm Pharmaceuticals (setmelanotide; disclosed)
Scope limitsopen-label (unblinded)